216 related articles for article (PubMed ID: 32027209)
1. Bifunctional Aptamer-Doxorubicin Conjugate Crosses the Blood-Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells.
Macdonald J; Denoyer D; Henri J; Jamieson A; Burvenich IJG; Pouliot N; Shigdar S
Nucleic Acid Ther; 2020 Apr; 30(2):117-128. PubMed ID: 32027209
[TBL] [Abstract][Full Text] [Related]
2. Development of a Bifunctional Aptamer Targeting the Transferrin Receptor and Epithelial Cell Adhesion Molecule (EpCAM) for the Treatment of Brain Cancer Metastases.
Macdonald J; Henri J; Goodman L; Xiang D; Duan W; Shigdar S
ACS Chem Neurosci; 2017 Apr; 8(4):777-784. PubMed ID: 28010059
[TBL] [Abstract][Full Text] [Related]
3. Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer.
Subramanian N; Raghunathan V; Kanwar JR; Kanwar RK; Elchuri SV; Khetan V; Krishnakumar S
Mol Vis; 2012; 18():2783-95. PubMed ID: 23213278
[TBL] [Abstract][Full Text] [Related]
4. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro.
Alibolandi M; Ramezani M; Sadeghi F; Abnous K; Hadizadeh F
Int J Pharm; 2015 Feb; 479(1):241-51. PubMed ID: 25529433
[TBL] [Abstract][Full Text] [Related]
5. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
6. CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1.
Erin N; Dilmaç S; Curry A; Duymuş Ö; Tanriover G; Prodeus A; Gariepy J; Gorczynski RM
Cancer Immunol Immunother; 2020 Jan; 69(1):103-114. PubMed ID: 31811336
[TBL] [Abstract][Full Text] [Related]
7. A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer.
Li J; Cai P; Shalviri A; Henderson JT; He C; Foltz WD; Prasad P; Brodersen PM; Chen Y; DaCosta R; Rauth AM; Wu XY
ACS Nano; 2014 Oct; 8(10):9925-40. PubMed ID: 25307677
[TBL] [Abstract][Full Text] [Related]
8. Anti-Proliferative Effect of Doxorubicin-Loaded AS1411 Aptamer on Colorectal Cancer Cell.
Lohlamoh W; Soontornworajit B; Rotkrua P
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2209-219. PubMed ID: 34319045
[TBL] [Abstract][Full Text] [Related]
9. Anti-epithelial cell adhesion molecule RNA aptamer-conjugated liposomal doxorubicin as an efficient targeted therapy in mice bearing colon carcinoma tumor model.
Mashreghi M; Zamani P; Karimi M; Mehrabian A; Arabsalmani M; Zarqi J; Moosavian SA; Jaafari MR
Biotechnol Prog; 2021 May; 37(3):e3116. PubMed ID: 33369269
[TBL] [Abstract][Full Text] [Related]
10. EpCAM-Targeting Aptamer Radiotracer for Tumor-Specific PET Imaging.
Li F; Zeng Z; Hamilton D; Zu Y; Li Z
Bioconjug Chem; 2021 Jun; 32(6):1139-1145. PubMed ID: 34014641
[TBL] [Abstract][Full Text] [Related]
11. Aptamer-mediated doxorubicin delivery reduces HCC burden in 3D organoids model.
Zhou K; Huo X; Nguyen R; Bae SDW; Han S; Zhang Z; Duan W; Yuen L; Lam V; George J; Qiao L
J Control Release; 2022 Jan; 341():341-350. PubMed ID: 34848243
[TBL] [Abstract][Full Text] [Related]
12. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro.
Liu Z; Duan JH; Song YM; Ma J; Wang FD; Lu X; Yang XD
J Transl Med; 2012 Jul; 10():148. PubMed ID: 22817844
[TBL] [Abstract][Full Text] [Related]
13. ssDNA Aptamer Specifically Targets and Selectively Delivers Cytotoxic Drug Doxorubicin to HepG2 Cells.
Yu G; Li H; Yang S; Wen J; Niu J; Zu Y
PLoS One; 2016; 11(1):e0147674. PubMed ID: 26808385
[TBL] [Abstract][Full Text] [Related]
14. EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex.
Subramanian N; Kanwar JR; Athalya PK; Janakiraman N; Khetan V; Kanwar RK; Eluchuri S; Krishnakumar S
J Biomed Sci; 2015 Jan; 22():4. PubMed ID: 25576037
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluation of therapy targeting epithelial-cell adhesion-molecule aptamers for non-small cell lung cancer.
Alibolandi M; Ramezani M; Abnous K; Sadeghi F; Atyabi F; Asouri M; Ahmadi AA; Hadizadeh F
J Control Release; 2015 Jul; 209():88-100. PubMed ID: 25912964
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effects of aptamer-doxorubicin conjugates in an ovarian cancer cell line.
Henri JL; Nakhjavani M; McCoombe S; Shigdar S
Biochimie; 2023 Jan; 204():108-117. PubMed ID: 36155804
[TBL] [Abstract][Full Text] [Related]
17. Environmentally Self-Adaptative Nanocarriers Suppress Glioma Proliferation and Stemness via Codelivery of shCD163 and Doxorubicin.
Liu J; Zhang Y; Chen T; Chen H; He H; Jin T; Wang J; Ke Y
ACS Appl Mater Interfaces; 2020 Nov; 12(47):52354-52369. PubMed ID: 33196179
[TBL] [Abstract][Full Text] [Related]
18. Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages.
Zhang T; Lip H; He C; Cai P; Wang Z; Henderson JT; Rauth AM; Wu XY
Adv Healthc Mater; 2019 Sep; 8(18):e1900543. PubMed ID: 31348614
[TBL] [Abstract][Full Text] [Related]
19. The application of aptamer 5TR1 in triple negative breast cancer target therapy.
Luo S; Wang S; Luo N; Chen F; Hu C; Zhang K
J Cell Biochem; 2018 Jan; 119(1):896-908. PubMed ID: 28671278
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth.
Zheng J; Zhao S; Yu X; Huang S; Liu HY
Theranostics; 2017; 7(5):1373-1388. PubMed ID: 28435472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
